Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sangamo Therapeutics Inc

0.4600
-0.2868-38.40%
Post-market: 0.47950.0195+4.24%19:59 EDT
Volume:17.50M
Turnover:8.09M
Market Cap:103.37M
PE:-0.95
High:0.4954
Open:0.4700
Low:0.4201
Close:0.7468
Loading ...

Truist Upgrades Sangamo Therapeutics to Buy From Hold, Reinstates Price Target at $7

MT Newswires Live
·
13 Dec 2024

Sangamo Therapeutics Shares up 3.3% After FDA Clears Application to Start Trial for Pain Treatment

THOMSON REUTERS
·
20 Nov 2024

Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts

Simply Wall St.
·
20 Nov 2024

BUZZ-Sangamo Therapeutics rises after FDA clears application to start trial for pain treatment

Reuters
·
20 Nov 2024

Sangamo Therapeutics Shares up 12.2% Premarket After FDA Clears Application to Start Trial for Pain Treatment

THOMSON REUTERS
·
20 Nov 2024

BRIEF-Sangamo Therapeutics Announces U.S. FDA Clearance Of IND Application For ST-503

Reuters
·
20 Nov 2024

Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment

Dow Jones
·
20 Nov 2024

Sangamo gets FDA clearance of IND application for ST-503 in iSFN

TIPRANKS
·
20 Nov 2024

Sangamo up 11% at $2.17 on FDA clearing IND for ST-503

TIPRANKS
·
20 Nov 2024

Sangamo Therapeutics Announces U.S. FDA Clearance of Ind Application for St-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

THOMSON REUTERS
·
20 Nov 2024

Sangamo Therapeutics Inc - to Initiate Phase 1/2 Study for St-503 in Mid-2025

THOMSON REUTERS
·
20 Nov 2024

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

Business Wire
·
20 Nov 2024

Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.
·
15 Nov 2024

Sangamo Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
15 Nov 2024